Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

ErbB4 antagonists

a technology of erbb4 and antagonists, applied in the field of erbb4 antagonists, can solve the problems of stenosis including vascular stenosis and restenosis, and achieve the effect of reducing heregulin binding and high affinity

Inactive Publication Date: 2007-04-26
GERRITSEN MARY E +1
View PDF11 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a method for controlling the growth and migration of smooth muscle cells in blood vessels and airways. This is achieved by using an antagonist of a native receptor called ErbB4. The antagonist can be an immunoglobulin or an antibody that targets the receptor. The method can prevent or treat stenosis, a condition where the blood vessels or airways become narrowed or obstructed. The antagonist can be administered as an injection or infusion and can also be introduced into cells in the patient using a nucleic acid. The invention is useful for treating hypertension associated with vascular stenosis and airway passage obstruction."

Problems solved by technology

The excessive proliferation or migration of smooth muscle cells such as vascular smooth muscle cells may result in stenosis including vascular stenosis and restenosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ErbB4 antagonists
  • ErbB4 antagonists
  • ErbB4 antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction, Isolation and Biochemical Characterization of Immunoadhesins and Chimeric Heteromultimer Immunoadhesins

[0225] A unique Mlu I site was engineered into a plasmid expressing human IgG heavy chain (pDR, a gift from J. Ridgeway and P. Carter, Genentech, Inc.) at the region encoding the hinge domain of the immunoglobulin. Mlu I sites were also engineered into a set of ErbB4 expression plasmids at the region encoding the ECD / TM junctions of these receptors. All mutagenesis were performed using the Kunkel method (Kunkel, T., Proc. Natl. Acad. Sci. U.S.A. 82:488 (1985)). The Mlu I sites were utilized to make the appropriate ErbB4-IgG fusion constructs. The fusion junction of the ErbB-IgG chimera was: G640ErbB4-(TR)-DKTH224VH where the amino acid numbering of the ErbB4 polypeptide is described in Plowman et al. (Plowman, G. D. et al., (1993a) PNAS USA 90:1746-1750). The conserved TR sequence is derived from the Mlu I site. The sequence of the Fc region used in the preparation o...

example 2

Effect of ErbB4-IgG Immunoadhesin on Human Aortic Smooth Muscle Cell Proliferation

[0229] Human aortic smooth muscle cells (Clonetics) were seeded at about 50% confluent density (5000 cells / well) in 96 well tissue culture plates and incubated overnight in SM2 media (Clonetics). Next day, the media was changed to M199 supplemented with ITS (1×), 2 mM L-glutamine, 50 μg / ml ascorbic acid, 26.5 mM NaHCO3, 100 U / ml penicillin, 100 U / ml streptomycin and 0.1% (v / v) fetal bovine serum. The cells were further incubated for 16 h. The cells were then treated with either Her4-IgG (400 nM) or buffer for 1 h, followed by treatment with PDGF (100 ng / ml) for 40 h. Control cells were left untreated to estimate the basal level of cell growth. An aliquot of BrdU (10 μl / well of a 10 μM solution of 5-bromo 2′-deoxyuridine prepared in PBS) was added and the cells were incubated for an additional 2 h. Cell proliferation was monitored by quantitating BrdU incorporation using BrdU ELISA (Cell proliferation k...

example 3

Effect of ErbB4-IgG Immunoadhesin on Human Aortic Smooth Muscle Cell Migration

[0231] Human aortic smooth muscle cells were trypsinized and resuspended at a concentration of 5×105 cells per ml in DME containing 10% FBS. Cells were pre-incubated with Her4-IgG (400 nM) or buffer for 15 min. The lower wells of ChemoTX chemotaxis chambers (Neuroprobe Inc., Cat 116-8) were filled with 300 μl of a solution of 2 U / ml human thrombin or buffer (PBS) negative control. A filter was mounted on top of the chamber and the smooth muscle cells (buffer or ErbB4 treated) were added to the top wells in a volume of 50 μl. The plate and filter were covered with the clear plastic lid and incubated for 3 h at 37° C. in humidified air with 5% CO2. At the end of the incubation, filters were removed and the top sides were wiped with a Q-tip to remove any remaining cells. The filters were stained with Dif-Quick staining solution and the number of cells migrated to the bottom of the filter were counted using a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
final volumeaaaaaaaaaa
Login to View More

Abstract

The present invention concerns methods and means for controlling excessive proliferation and / or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 362,380, filed Aug. 6, 2003, which is the National Stage Application filed under 35 U.S.C. §371 of PCT / US01 / 26984, filed Aug. 29, 2001, which is a continuation of U.S. patent application Ser. No. 09 / 940,101 filed Aug. 27, 2001, now abandoned, which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 60 / 265,516 filed Jan. 31, 2001 and of U.S. Provisional Patent Application Ser. No. 60 / 229,679 filed Sep. 1, 2000, the entire disclosures of which are hereby expressly incorporated by reference.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention concerns methods and means for controlling excessive proliferation and / or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identifica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395G01N33/50A61K38/00A61K45/00A61K48/00A61P9/00A61P9/12A61P13/10A61P21/00C07K14/475C07K14/82C07K16/32C07K16/40C12N15/02C12P21/08G01N33/15G01N33/53G01N33/566
CPCA61K38/00C07K14/4756C07K14/82C07K16/32C07K2316/96C07K2317/92C07K2319/00C07K2319/30G01N33/5061C07K2317/73C07K2317/76A61P13/10A61P21/00A61P9/00A61P9/12
Inventor GERRITSEN, MARY E.SLIWKOWSKI, MARK X.
Owner GERRITSEN MARY E
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com